ArticleThe Journal of infectious diseases2020
Global Risk and Elimination of Yellow Fever Epidemics.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Review
- Ebola Virus Disease: Uniquely Challenging Among the Viral Hemorrhagic Fevers.Open forum infectious diseases · 2025Review
- Dynamic analysis and optimal control of competitive information dissemination model.Scientific reports · 2024Article
- A safer cell-based yellow fever live attenuated vaccine protects mice against YFV infection.iScience · 2024Article
- A proposed One Health approach to control yellow fever outbreaks in Uganda.One health outlook · 2024Review
- The global incidence and trends of three common flavivirus infections (Dengue, yellow fever, and Zika) from 2011 to 2021.Frontiers in microbiology · 2024Article
- Fractional Dosing of Yellow Fever Live Attenuated 17D Vaccine: A Perspective.Infection and drug resistance · 2023Article
- Retrospective molecular investigation of Mayaro and Oropouche viruses at the human-animal interface in West-central Brazil, 2016-2018.PloS one · 2022Article
- Yellow fever in Asia-a risk analysis.Journal of travel medicine · 2021Article
- Re-emergence of yellow fever in the neotropics - quo vadis?Emerging topics in life sciences · 2020Review
- Article
- High Rate of Non-Human Feeding byViruses · 2020Article
- Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.Current treatment options in infectious diseases · 2020Review
- Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever.Current treatment options in infectious diseases · 2020Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYellow fever (YF) is a vector-borne viral hemorrhagic disease endemic in Africa and Latin America. In 2016, the World Health Organization (WHO) developed the Eliminate YF Epidemics strategy aiming at eliminating YF epidemics by 2026.
methodsWe developed a spatiotemporal model of YF, accounting for the impact of temperature, vector distribution, and socioeconomic factors on disease transmission. We validated our model against previous estimates of YF basic reproductive number (R0). We used the model to estimate global risk of YF outbreaks and vaccination efforts needed to achieve elimination of YF epidemics.
resultsWe showed that the global risk of YF outbreaks is highly heterogeneous. High-risk transmission areas (R0 > 6) are mainly found in West Africa and the Equatorial region of Latin America. We showed that vaccination coverage needed to eliminate YF epidemics in an endemic country varies substantially between districts. In many endemic countries, a 90% vaccination coverage is needed to achieve elimination. However, in some high-risk districts in Africa, a 95% coverage may be required.
conclusionsGlobal elimination of YF epidemics requires higher population-level immunity than the 80% coverage recommended by the WHO. Optimal YF vaccination strategy should be tailored to the risk profile of each endemic country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.